drugset / Trial / NCT06212245
A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
NaSingle-groupOpen-labelTreatment
Summary
To assess the efficacy and safety of Inebilizumab in Chinese adult patients with neuromyelitis optica spectrum disorders.
Timeline
- Start
- 2024-02-25
- Primary completion
- 2024-12-25
- Completion
- 2025-06-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Inebilizumab | Monoclonal antibody | 300 mg | Intravenous |